Studies were performed onWistar strain rats aged 1–720 days. Immunocytochemical reactions were used to detect calcitonin, somatostatin, calcitonin gene-related peptide (CGRP), cholecystokinin, serotonin, neuron-specific enolase (NSE), secretory protein-I, chromogranin and Ca-binding protein. In the parafollicular cells of the rat, the presence of calcitonin, somatostatin, CGRP, NSE and secretory protein-I could be demonstrated. The number of parafollicular cells increased with the age of animals, and the increase was particularly pronounced in the early postnatal period and after the first year of age. The number of somatostatin-immunoreactive cells decreased after birth and increased again after the first year of age. The number of calcitonin-immunoreactive cells increased in the early postnatal period independently of the increase in parafollicular cell number, forming frequently tumor-like outgrowths in 2-year-old animals. A small proportion of these outgrowths contained no calcitonin even if they did contain somatostatin, CGRP and NSE immunoreactivity. Evident changes in immunoreactivity in the first days after birth may reflect the sudden change in environment and may be associated with growth and differentiation. In any period of life, CGRP- and NSE-immunoreactive cells have constituted the most numerous groups and, therefore, the respective antigens seem to represent the most suitable markers of parafollicular cells in the rat.

Keywords:
Parafollicular (C) cells, Postnatal development, Immunoreactivity, Thyroid, Rat
This content is only available via PDF.
© 1987 S. Karger AG, Basel
1987
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.